U.S. Markets for Obesity Drugs & Devices
U.S. Markets for Obesity Drugs & Devices
$5,250.00
U.S. Markets for Obesity Drugs & Devices
Publisher: Meddevicetracker
- Description
- Contents
- Samples
According to National Health and Nutrition Examination Survey (NHANES), approximately 35%, or nearly one out of three adults age 20 years or older were classified as obese in 2012 (the latest available statistics) based on a BMI of 30 kg/m2 or greater. This translates to more than 100 million obese people in the U.S.—a staggering number. Obesity has become such as concern due to increasing prevalence and the rise of serious health-related co-morbidities, such as type 2 diabetes, that it has recently been recognized by the American Medical Association, as well as other medical and government organizations, as a chronic disease. Due to the fact that type 2 diabetes and obesity are closely linked, the rise of obesity is increasing the prevalence of diabetes, making it critical to develop improved medical treatments to more effectively treat both conditions.
The fact that the overweight, obese and morbidly obese population remains vastly undertreated (in the U.S. and worldwide) bodes very well for next-generation obesity drugs and devices, as it leaves significant room for companies to profit and grow revenues in the coming decade in a virtually untapped U.S. market, expected to be valued at more than $1.8 billion by the year 2020.
This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Obesity Drugs and Devices Market. Specifically, this report covers leading and emerging prescription-based weight loss (obesity) drugs, and minimally invasive medical devices, including: laparoscopic adjustable gastric banding (LAGB) systems, intragastric balloon systems, implantable gastric stimulation devices, and other emerging device-based technologies, including nonsurgical/incisionless, transorally inserted or next-generation minimally invasive weight loss device therapies.
In 2014, the total, combined U.S. market for “new” obesity drugs and (minimally invasive medical) devices for the treatment of obesity was estimated at approximately $374.7 million. Over the forecast period, the total market is expected to advance at a healthy, double-digit compound annual rate of 32.4%, from an estimated $455.4 million in 2015 to an estimated $1,852.1 million in the year 2020.
Table of Contents
EXECUTIVE SUMMARY…………………………………………………………………………. ES-1
i. U.S. Obesity Drugs & Devices Market…………………………………….. ES-2
Ii. Methodology……………………………………………………………………….. ES-3
Exhibit ES-1: U.S. Obesity Drugs & Devices Market, 2013-2020…………………… ES-4
1. OBESITY DRUGS …………………………………………………………………………… 1-1
1.1 Leading Obesity Drugs ……………………………………………………………. 1-1
1.1.1 Genentech/Roche Group (Xenical) …………………………….. 1-2
1.1.2 Vivus (Qsymia)………………………………………………………..1–8
1.1.3 Arena Pharmaceuticals/Eisai (Belviq)………………………… 1-12
1.1.4 Orexigen Therapeutics/Takeda (Contrave) ………………… 1-15
1.2 Emerging Obesity Drugs ……………………………………………………….. 1-18
1.2.1 Gelesis (Gelesis100)………………………………………………. 1-24
1.2.2 Hanmi Pharmaceuticals (LAPS CA-Exendin-4/
HPP4404)……………………………………………………………… 1-27
1.2.3 Novo Nordisk (Saxenda) …………………………………………. 1-28
1.2.3.1 Victoza (liraglutide)…………………………………… 1-31
1.2.4 Orexigen Therapeutics (Empatic)……………………………… 1-32
1.2.5 Rhythm Pharmaceuticals (RM-493) ………………………….. 1-32
1.2.6 Zafgen (Beloranib)………………………………………………….. 1-33
1.3 Market Analysis ……………………………………………………………………. 1-35
1.3.1 Market Forecast …………………………………………………….. 1-35
1.3.1.1 Market Drivers …………………………………………. 1-36
1.3.1.2 Market Limiters………………………………………… 1-38
1.3.2 Competitive Analysis ………………………………………………. 1-39
Exhibit 1-1: 2015, FDA Approved Obesity Drugs …………………………………………. 1-3
Exhibit 1-2: Xenical, SWOT Analysis………………………………………………………….. 1-9
Exhibit 1-3: Qsymia, SWOT Analysis ……………………………………………………….. 1-13
Exhibit 1-4: Belviq, SWOT Analysis………………………………………………………….. 1-16
Exhibit 1-5: Contrave, SWOT Analysis……………………………………………………… 1-19
Exhibit 1-6: 2015, Selected Obesity Drugs Recently FDA Approved or
Under Development………………………………………………………………. 1-20
Exhibit 1-7: Gelesis100 Mechanism of Action ……………………………………………. 1-25
Exhibit 1-8: New Obesity Drugs, Market Forecast, 2013-2020……………………… 1-37
2015 Medtech Insight i #A153
U.S. Markets for Obesity Drugs & Devices Table of Contents
Exhibit 1-9: 2013, New Obesity Drugs Market, Share by Supplier ………………… 1-40
Exhibit 1-10: 2014, New Obesity Drugs Market, Share by Supplier ………………… 1-41
2. LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING SYSTEMS ………. 2-1
2.1 Leading LAGB Systems ………………………………………………………….. 2-5
2.1.1 Apollo Endosurgery ………………………………………………….. 2-8
2.1.2 Ethicon Endo-Surgery/Johnson & Johnson………………… 2-11
2.1.3 Other LAGB Systems (Available Outside the U.S.)……… 2-25
2.1.3.1 Agency for Medical Innovations………………….. 2-25
2.1.3.2 Cousin Biotech ………………………………………… 2-26
2.1.3.3 Hélioscopie……………………………………………… 2-26
2.1.3.4 Médical Innovation Développement ……………. 2-29
2.2 Market Analysis ……………………………………………………………………. 2-29
2.2.1 Procedure Volumes Forecast…………………………………… 2-29
2.2.2 Market Forecast …………………………………………………….. 2-37
2.2.2.1 Market Drivers …………………………………………. 2-37
2.2.2.2 Market Limiters………………………………………… 2-40
2.2.3 Competitive Analysis ………………………………………………. 2-41
Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/
Bariatric Surgery…………………………………………………………………….. 2-3
Exhibit 2-2: 2015, Laparoscopic Adjustable Gastric Banding Systems ……………. 2-6
Exhibit 2-3: Apollo EndoSurgery’s LAP-BAND …………………………………………… 2-12
Exhibit 2-4: Key Benefits and Risks of the LAP-BAND Procedure ………………… 2-13
Exhibit 2-5: Excess Weight Loss with the LAP-BAND System Compared to
Roux-en-Y Gastric Bypass at 3 Years and Beyond……………………. 2-15
Exhibit 2-6: Ethicon Endo-Surgery’s Curved Adjustable Gastric Endo Band,
Features and Benefits …………………………………………………………… 2-16
Exhibit 2-7: Comparison of Gastric Banding, Gastric Bypass, and Sleeve
Gastrectomy ………………………………………………………………………… 2-20
Exhibit 2-8: Agency for Medical Innovations’ Soft Gastric Band Premium………. 2-27
Exhibit 2-9: Cousin Biotech’s Bioring Adjustable Gastric Band …………………….. 2-28
Exhibit 2-10: Hélioscopie’s Heliogast HAGA Adjustable Gastric Band…………….. 2-30
Exhibit 2-11: Médical Innovation Développement’s MIDBAND
Adjustable Gastric Band ………………………………………………………… 2-31
Exhibit 2-12: Laparoscopic Adjustable Gastric Banding, Procedure Volumes
Forecast, 2013-2020 …………………………………………………………….. 2-33
2015 Medtech Insight ii #A153
U.S. Markets for Obesity Drugs & Devices Table of Contents
Exhibit 2-13: Estimated Number of Bariatric Surgeries, U.S. Procedure
Volumes Forecast, 2013-2020 ……………………………………………….. 2-34
Exhibit 2-14: 2015 and 2020, Comparison of Estimated Bariatric Surgical
Procedure Volumes, by Percentage and Type of Surgery…………… 2-36
Exhibit 2-15: Laparoscopic Adjustable Gastric Banding, Market Forecast,
2013-2020 …………………………………………………………………………… 2-38
Exhibit 2-16: 2013, Laparoscopic Adjustable Gastric Banding Systems Market,
Share by Supplier…………………………………………………………………. 2-42
Exhibit 2-17: 2014, Laparoscopic Adjustable Gastric Banding Systems Market,
Share by Supplier…………………………………………………………………. 2-43
3. INTRAGASTRIC BALLOON SYSTEMS …………………………………………….. 3-1
3.1 Apollo Endosurgery ………………………………………………………………… 3-2
3.2 Hélioscopie……………………………………………………………………………. 3-4
3.3 ReShape Medical …………………………………………………………………… 3-4
3.4 Spatz FGIA……………………………………………………………………………. 3-8
3.5 Obalon Therapeutics …………………………………………………………….. 3-14
3.6 Market Analysis ……………………………………………………………………. 3-15
3.6.1 Market Drivers ……………………………………………………….. 3-21
3.6.2 Market Limiters………………………………………………………. 3-22
Exhibit 3-1: Apollo Endosurgery’s Orbera Managed Weight Loss System……….. 3-3
Exhibit 3-2: Hélioscopie’s Heliosphere Intragastric Balloon……………………………. 3-5
Exhibit 3-3: ReShape Duo Intragastric Balloon System ………………………………… 3-7
Exhibit 3-4: REDUCE Pivotal Trial Results………………………………………………….. 3-9
Exhibit 3-5: The Spatz Adjustable Balloon System……………………………………… 3-11
Exhibit 3-6: Risks of Intragastric Balloon Placement …………………………………… 3-12
Exhibit 3-7: The Spatz Adjustable Balloon Procedure…………………………………. 3-13
Exhibit 3-8: The Obalon Gastric Balloon System Features and
Possible Complications …………………………………………………………. 3-16
Exhibit 3-9: Intragastric Balloon Therapy, Procedure Volumes Forecast,
2015-2020 …………………………………………………………………………… 3-19
Exhibit 3-10: Intragastric Balloon Systems, Market Forecast, 2015-2020 ………… 3-20
4. IMPLANTABLE VAGAL BLOCKING THERAPY…………………………………. 4-1
4.1 EnteroMedics…………………………………………………………………………. 4-2
4.2 MetaCure…………………………………………………………………………….. 4-10
2015 Medtech Insight iii #A153
U.S. Markets for Obesity Drugs & Devices Table of Contents
4.3 Market Analysis ……………………………………………………………………. 4-13
4.3.1 Market Drivers ……………………………………………………….. 4-18
4.3.2 Market Limiters………………………………………………………. 4-19
Exhibit 4-1: 2015, Implantable Pulse Generators Developed for the Treatment
of Obesity ……………………………………………………………………………… 4-4
Exhibit 4-2: EnteroMedics’ Maestro System………………………………………………… 4-7
Exhibit 4-3: Overview of EnteroMedics’ VBLOC Therapy and
Vagus Nerve Function…………………………………………………………….. 4-8
Exhibit 4-4: Potential Benefits and Risks of VBLOC Therapy…………………………. 4-9
Exhibit 4-5: Comparison of VBLOC Therapy, Laparoscopic Banding, and
Gastric Bypass …………………………………………………………………….. 4-10
Exhibit 4-6: MetaCure’s DIAMOND (TANTALUS) Gastric Stimulation System .. 4-13
Exhibit 4-7: Implantable VBLOC Therapy Devices, EnteroMedics,
Procedure Volumes Forecast, 2015-2020………………………………… 4-17
Exhibit 4-8: Implantable VBLOC Therapy Devices, EnteroMedics, Market
Forecast, 2015-2020 …………………………………………………………….. 4-18
5. OTHER EMERGING MEDICAL DEVICE TECHNOLOGIES………………….. 5-1
5.1 Aspire Bariatrics …………………………………………………………………….. 5-1
5.2 BAROnova ……………………………………………………………………………. 5-6
5.3 EndoSphere, Inc…………………………………………………………………….. 5-7
5.4 GI Dynamics………………………………………………………………………….. 5-7
5.5 Onciomed ……………………………………………………………………………. 5-11
5.6 Scientific Intake ……………………………………………………………………. 5-12
5.7 TransEnterix ………………………………………………………………………… 5-15
5.8 USGI Medical ………………………………………………………………………. 5-16
5.9 Others…………………………………………………………………………………. 5-21
Exhibit 5-1: 2015, Selected Emerging Medical Device Technologies
for the Treatment of Obesity…………………………………………………….. 5-2
Exhibit 5-2: Aspire Bariatric’s AspireAssist………………………………………………….. 5-5
Exhibit 5-3: EndoSphere’s SatiSphere ……………………………………………………….. 5-8
Exhibit 5-4: GI Dynamic’s EndoBarrier Gastrointestinal Liner and Procedure…. 5-10
Exhibit 5-5: Scientific Intake’s SMART Device …………………………………………… 5-14
Exhibit 5-6: USGI Medical’s Incisionless Operating Platform ……………………….. 5-18
Exhibit 5-7: Primary Obesity Surgery, Endolumenal……………………………………. 5-20
2015 Medtech Insight iv #A153
U.S. Markets for Obesity Drugs & Devices Table of Contents
TOTAL U.S. OBESITY DRUGS AND DEVICES MARKET……………………………… 6-1
i. New Obesity Drugs Market………………………………………………………. 6-1
ii. Obesity Devices Market…………………………………………………………… 6-1
Exhibit 6-1: U.S. Obesity Drugs & Devices Market, 2013-2020………………………. 6-5
Exhibit 6-2: U.S. New Obesity Drugs Market, 2013-2020………………………………. 6-9
Exhibit 6-3: U.S. Obesity Devices Market, 2013-2020…………………………………. 6-10
APPENDIX: COMPANY LISTING
Exhibit 1-5: Contrave, SWOT Analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
U.S. Markets for Critical Care Patient Management Products 
Sign up to the